The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.
Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...
Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...
VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines
(RTTNews) - Anixa Biosciences, Inc. (ANIX) has entered into a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions ...
If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.
On Tuesday, Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI ...
Stay updated on market trends for ANIX. EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines Anixa Biosciences ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback